|
|
Tradename |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
Accofil |
Belgium, Croatia, Germany, Great Britain |
Duperan |
Chile |
Filgen |
Argentina, Chile |
Foltran |
Chile |
Granulokine |
Brazil, Greece, Italy |
Hebervital |
Colombia |
Inmunef |
Colombia, Mexico |
Leucosos |
Colombia |
Lioplim |
Chile |
Neupogen |
Australia, Austria, Belgium, Canada, Chile, Colombia, Denmark, Ecuador, Egypt, Finland, France, Germany, Great Britain, Iran, Ireland, Luxembourg, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Norway, Poland, Portugal, Saudi Arabia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, United States of America, Venezuela |
Neutromax |
Argentina |
Neutropine |
Argentina |
Nivestim |
Belgium, France, Germany, Great Britain, Netherlands, Norway |
Ratiograstim |
Austria, Germany, Great Britain, Sweden |
Tevagrastim |
Belgium, Brazil, Chile, Croatia, Germany, Great Britain, Netherlands, Norway, Spain, Sweden, Switzerland |
|
|
|
|
References : Filgrastim |
|
|
Type |
Publication |
99 |
Journal |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
104 |
Journal |
Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189. |
182 |
Journal |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
Journal |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
2269 |
Journal |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
3128 |
Manufacturer |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013 |
3249 |
Journal |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3256 |
Journal |
Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56. |
3474 |
Manufacturer |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
3618 |
Manufacturer |
Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014 |
3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
4055 |
Journal |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
4380 |
Manufacturer |
Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019 |
4471 |
Manufacturer |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019 |
4521 |
Journal |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020 |
4650 |
Manufacturer |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |
|
|